Evidence map›Paper›PMID 34273292›Full record

ArticleLancet (London, England)2021

Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.

Kate Causey, Nancy Fullman, Reed J D Sorensen, Natalie C Galles, Peng Zheng, Aleksandr Aravkin, M Carolina Danovaro-Holliday, Ramon Martinez-Piedra, Samir V Sodha, Martha Patricia Velandia-González and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 244 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
244citing papers in PubMed, 8 pooled it
43.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

244 citing papers in PubMed, 8 syntheses or guidelines pooled it, 435 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

184 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Kate CauseyInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Nancy FullmanInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Reed J D SorensenInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Natalie C GallesInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Peng ZhengInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Aleksandr AravkinInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA; Department of Applied Mathematics, University of Washington, Seattle, WA, USA.
M Carolina Danovaro-HollidayDepartment of Immunization, Vaccines and Biologicals, Word Health Organization, Geneva, Switzerland.
Ramon Martinez-PiedraPan American Health Organization, Comprehensive Family Immunization Unit, Washington, DC, USA.
Samir V SodhaDepartment of Immunization, Vaccines and Biologicals, Word Health Organization, Geneva, Switzerland.
Martha Patricia Velandia-GonzálezPan American Health Organization, Comprehensive Family Immunization Unit, Washington, DC, USA.
Marta Gacic-DoboDepartment of Immunization, Vaccines and Biologicals, Word Health Organization, Geneva, Switzerland.
Emma CastroInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Jiawei HeInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Megan SchippInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Amanda DeenInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Simon I HayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Stephen S LimInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
Jonathan F MosserInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA; Pediatric Infectious Diseases, Seattle Children's Hospital, Seattle, WA, USA. Electronic address: jmosser@uw.edu.
Institute for Health Metrics and Evaluation · USUniversity of Washington · USWorld Health Organization · CHWorld Health Organization Regional Office for the Americas · USSeattle Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic and efforts to reduce SARS-CoV-2 transmission substantially affected health services worldwide. To better understand the impact of the pandemic on childhood routine immunisation, we estimated disruptions in vaccine coverage associated with the pandemic in 2020, globally and by Global Burden of Disease (GBD) super-region.

methodsFor this analysis we used a two-step hierarchical random spline modelling approach to estimate global and regional disruptions to routine immunisation using administrative data and reports from electronic immunisation systems, with mobility data as a model input. Paired with estimates of vaccine coverage expected in the absence of COVID-19, which were derived from vaccine coverage models from GBD 2020, Release 1 (GBD 2020 R1), we estimated the number of children who missed routinely delivered doses of the third-dose diphtheria-tetanus-pertussis (DTP3) vaccine and first-dose measles-containing vaccine (MCV1) in 2020.

findingsGlobally, in 2020, estimated vaccine coverage was 76·7% (95% uncertainty interval 74·3-78·6) for DTP3 and 78·9% (74·8-81·9) for MCV1, representing relative reductions of 7·7% (6·0-10·1) for DTP3 and 7·9% (5·2-11·7) for MCV1, compared to expected doses delivered in the absence of the COVID-19 pandemic. From January to December, 2020, we estimated that 30·0 million (27·6-33·1) children missed doses of DTP3 and 27·2 million (23·4-32·5) children missed MCV1 doses. Compared to expected gaps in coverage for eligible children in 2020, these estimates represented an additional 8·5 million (6·5-11·6) children not routinely vaccinated with DTP3 and an additional 8·9 million (5·7-13·7) children not routinely vaccinated with MCV1 attributable to the COVID-19 pandemic. Globally, monthly disruptions were highest in April, 2020, across all GBD super-regions, with 4·6 million (4·0-5·4) children missing doses of DTP3 and 4·4 million (3·7-5·2) children missing doses of MCV1. Every GBD super-region saw reductions in vaccine coverage in March and April, with the most severe annual impacts in north Africa and the Middle East, south Asia, and Latin America and the Caribbean. We estimated the lowest annual reductions in vaccine delivery in sub-Saharan Africa, where disruptions remained minimal throughout the year. For some super-regions, including southeast Asia, east Asia, and Oceania for both DTP3 and MCV1, the high-income super-region for DTP3, and south Asia for MCV1, estimates suggest that monthly doses were delivered at or above expected levels during the second half of 2020.

interpretationRoutine immunisation services faced stark challenges in 2020, with the COVID-19 pandemic causing the most widespread and largest global disruption in recent history. Although the latest coverage trajectories point towards recovery in some regions, a combination of lagging catch-up immunisation services, continued SARS-CoV-2 transmission, and persistent gaps in vaccine coverage before the pandemic still left millions of children under-vaccinated or unvaccinated against preventable diseases at the end of 2020, and these gaps are likely to extend throughout 2021. Strengthening routine immunisation data systems and efforts to target resources and outreach will be essential to minimise the risk of vaccine-preventable disease outbreaks, reach children who missed routine vaccine doses during the pandemic, and accelerate progress towards higher and more equitable vaccination coverage over the next decade.

fundingBill & Melinda Gates Foundation.

Indexed as

COVID-19Diphtheria-Tetanus-Pertussis VaccineMeasles VaccineChildGlobal HealthHumansModels, StatisticalVaccination CoverageDiphtheria-Tetanus-Pertussis VaccineMeasles Vaccine

Identifiers

PMID34273292
PMCPMC8285122
OpenAlexW3183723118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.